All patients had normal laboratory evaluations, including absolute neutrophil, lymphocyte, and monocyte counts and liver function assessments, at diagnosis and when metastasis manifested. in circulating CD3CD56dimNK cells and CD8+and double-negative CD3+CD56+NKT cells. ICOS+CD4+FoxP3+T regulatory cells and CD11b+CD14CD15+myeloid suppressor cells increased. Plasma levels of miR-20a, 125b, 146a, 155, 181a, and 223 were higher in the study patients at diagnosis compared to controls. Plasma levels of miR-20a, 125b, 146a, 155, and 223 increased, and miR-181a decreased when metastasis manifested. Alterations in immune regulatory miRs were also observed in CD3+, CD15+, and CD56+cell populations. == Conclusions == The development of metastasis in uveal melanoma 3-Nitro-L-tyrosine is usually associated with changes in immune effector and regulatory cells consistent with lessening tumor immune surveillance. These changes are associated with changes in plasma and cellular levels of immune regulatory miRs. The results may help guide uveal melanoma immunotherapy and biomarker development. Keywords:MicroRNA, Uveal melanoma, Biomarkers, Immune response == 1. Introduction == Melanoma of the eyes uveal tract is usually a rare, aggressive cancer with a high mortality rate because of the development of metastatic disease, primarily in the liver, that almost invariably is usually refractory to therapy (Singh et al., 2011). Immune mechanisms have been implicated in uveal melanoma progression. Mouse models have implicated cytostatic CD8+T cells (Eyles et al., 2010), natural killer (NK) cells (Dithmar et al., 2000;Yang et al., 2011), and pro-tumoral macrophages (Ly et al., 2010). PBX1 Several clinical observations suggest that immune responses are operational. In many solid tumors, including cutaneous melanoma, the presence of tumor infiltrating lymphocytes (TIL) confers a good prognosis. In uveal melanoma, TIL are associated with the development of metastatic disease. Tumor expression of MHC class I antigen, which is necessary for T-cell recognition but renders cells resistant to NK cells, is also associated with a poor prognosis (Blom et al., 1997). We have shown that elevated blood levels of beta2microglobulin, the soluble MHC class I heavy chain, are associated with tumor monosomy-3, which confers a poor prognosis (Triozzi et al., 2013). Specific HLA-C alleles encoding ligands for inhibitory NK receptors have been associated with disease-free survival (Maat et al., 2009). T regulatory (Treg), natural killer T (NKT), and myeloid derived suppressor cells (MDSC) have also been identified in the tumors or blood of patients (Niederkorn, 2009;McKenna et al., 2009;Mougiakakos et al., 2010;Bricard et al., 2009). Although immune responses are predominantly controlled at the transcriptional level, epigenetic mechanisms are increasingly being recognized. microRNAs (miRs) are small non-coding RNAs that regulate gene expression at the post-transcriptional level by either degrading or blocking translation of mRNA targets. They play important roles in oncogenesis, and the ability of miR expression profiling to distinguish different cancer types and classify their subtypes has been well-described. miRs also play important regulatory roles in a variety of cellular functions, including immune response, and several miRs with immune regulatory activities have been identified. Predominant among these are miR-125b, 146a, 155, 181a, 223, and miRs of the 1792 complex (Tsitsiou and Lindsay, 2009). Highly stable in the circulation, miRs hold great promise as a new class of blood biomarkers (Ferracin et al., 2010). Studies of circulating immune cells in patients with uveal melanoma have been primarily conducted in patients at diagnosis (McKenna et al., 2009;Many-Kubacka et al., 2005;Haynie et al., 1997). There is little information regarding circulating levels of immune effector and regulatory cells as patients progress to metastatic disease. How circulating miRs, immune regulatory or other, modulate with the progression of human cancer is also not known. In order to examine the immune mechanisms involved as well as to develop potential biomarkers of disease progression, we compare here immune cell and immune regulatory miRs levels of patients followed prospectively from primary diagnosis to metastatic disease. == 2. Patients and methods == == 2.1. Patients == Six consenting patients with uveal melanoma enrolled on a study approved by the Cleveland Clinic Institutional Review Board were evaluated. 3-Nitro-L-tyrosine Plasma was also obtained from healthy donors without ocular disease, also on an approved study. 3-Nitro-L-tyrosine At the time of diagnosis, each patient underwent comprehensive ophthalmic examination with supporting diagnostic studies. This included computed tomography scans of the chest, abdomen, and pelvis to rule out metastatic disease. Fine needle aspiration biopsy was performed in patients undergoing brachytherapy (plaque radiotherapy) at the time of plaque insertion. Chromosome 3 status was assessed by a fluorescencein situhybridization technique (Singh et al., 2012). Patients were followed clinically and radiographically using standard-of-care guidelines,.
